

Assessment of Patients' Experiences With Ofatumumab in Multiple Sclerosis: Findings From a Market Research Survey Conducted in the Netherlands

Gerald Hengstman¹; Willem Bouvy²; Jeroen Van Eijk³; Eric Hamers⁴; Mieke Hermans⁵; Floris De Kleermaeker⁵; Michaël Peeters⁶; Luuk Van Rooij⁷; Ronald Van de Ven²; Esther Zeinstra⁸

¹Upendo, Boxtel, The Netherlands; ²Department of Neurology, Diaconessenhuis Utrecht en Zeist, The Netherlands; ³Department of Neurology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands; ⁴Novartis Pharma BV, Amsterdam, The Netherlands; ⁵Department of Neurology, VieCuri Medical Center, Venlo, The Netherlands; ⁶Department of Neurology, Máxima Medical Center, Eindhoven, The Netherlands; ⁷Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands; ⁸Department of Neurology, Isala Hospital, Meppel, The Netherlands

SUMMARY

- 1 A market research survey was conducted by IPSOS in the Netherlands to understand real-world patients' experience with ofatumumab treatment and its impact on quality of life (QoL) in people with multiple sclerosis (MS)
- 2 Respondents were asked to fill out a 10-minute questionnaire to assess patients' background characteristics, patients' MS disease history, use of ofatumumab, experience with ofatumumab and impact of ofatumumab on daily life
- 3 The majority of respondents were positive about the ofatumumab user experience and had a satisfying QoL following ofatumumab treatment
- 4 This positive experience plays an important role in patient satisfaction and treatment adherence in clinical practice

INTRODUCTION

- When managing people with MS on disease-modifying therapies (DMTs), patients' experiences and their treatment satisfaction are important considerations besides the established efficacy and safety of DMTs
- Real-world evidence on patients' experiences and satisfaction with ofatumumab as a treatment option for relapsing MS is limited

OBJECTIVE

- To understand real-world patients' experience with ofatumumab treatment and its impact on QoL in people with MS

METHODS

SURVEY DESIGN



A market research survey was conducted via IPSOS in the Netherlands from April 2022 to April 2023 via an online questionnaire



People with relapsing MS diagnosis and within the reimbursement criteria of the Netherlands were recruited via flyers by the specialists in MS centres – Upendo, Jeroen Bosch Hospital, Maasstad Hospital, Máxima Medical Center, VieCuri Medical Center, Diaconessenhuis and Isala Hospital

QUESTIONNAIRES

- The respondents were asked to fill out a questionnaire of 20 questions on different parameters, divided into 5 sections



Patients' background characteristics



Patients' MS disease history



Use of ofatumumab



Experience with ofatumumab



Impact of ofatumumab on daily life


- It took about 10 minutes to complete the questionnaire
- Questions were single choice, multiple choice, multiple open text and array type

STATISTICAL ANALYSIS

- Both quantitative and qualitative data collection and analysis were part of this survey
- Survey results were summarised descriptively, and categorical variables were summarised using frequencies and percentages

RESULTS

PATIENTS' BACKGROUND CHARACTERISTICS



- Most patients live together with others (80%) and are not receiving additional care at home (70%), and do not work (61%)

MS DISEASE HISTORY

Patients diagnosed with MS



Mean self-assessed EDSS score



- Patients had been switched to ofatumumab from first- and second-line treatments and relatively often from ocrelizumab (39%)
- Most patients (53%) who switched to ofatumumab had a strong preference for treatment at home (median score: 1, on a Likert scale [1=Home treatment, 5=Hospital treatment])


USE OF OFATUMUMAB

- Reasons to switch to ofatumumab were disease activity (n=25), convenience of administration at home (n=24), side effects (n=19) and other (n=15)
- All patients were still using ofatumumab therapy at the time of survey

EXPERIENCE WITH OFATUMUMAB

- Over 90% of patients are positive about the ofatumumab user experience in terms of ease of use and administration (Figure 1)


Figure 1. User experience with ofatumumab



All values are depicted as percentages (%) unless specified otherwise

- Ofatumumab was associated with an improvement in QoL; a smaller proportion of patients using ofatumumab stated that they don't feel confident (30%), independent (3%), flexible (10%), free (9%) and felt frustrated (2%) (Figure 2)


Figure 2. Impact of ofatumumab on quality of life



All values are depicted as percentages (%) unless specified otherwise

- Most patients do not feel a negative impact of ofatumumab on independence; among the patients who work, the majority were neutral or positive on the effect of ofatumumab in improving productivity at work or during spare time (Figure 3)


Figure 3. Impact of ofatumumab on independence



All values are depicted as percentages (%) unless specified otherwise

- Majority of patients (51%) agree that ofatumumab is a more time-efficient treatment (Figure 4)
- A sizeable proportion of patients (41%) are neutral on whether ofatumumab reduces mental burden

Figure 4. Influence of ofatumumab on daily life



All values are depicted as percentages (%) unless specified otherwise. MS, multiple sclerosis

CONCLUSIONS

- The results show that people with MS consider monthly at-home subcutaneous treatment with ofatumumab favourable and convenient to use
- This positive experience plays an important role in patient satisfaction and treatment adherence in clinical practice

Abbreviations: DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; QoL, quality of life

Disclosures: Gerald Hengstman gives asked and unasked, paid and unpaid advice to many parties active in the field of MS including: BMS, Biogen, Coloplast, Janssen, Merck, Novartis, Roche and Sanofi. Willem Bouvy has participated in an advisory board for Novartis. Jeroen van Eijk has participated in advisory boards and oral presentations for Biogen, Roche, Merck, Genzyme, Novartis, Janssen, BMS. Eric Hamers is an employee of Novartis. Mieke Hermans, Floris de Kleermaeker, Michael Peeters, and Ronald van de Ven have nothing to disclose. Luuk van Rooij has served as PI for the REMODEL study for Novartis. Esther Zeinstra has participated in advisory boards and has nominations for Merck, Novartis, Genzyme and Roche.

Acknowledgments: This study was funded by Novartis Pharma BV, Amsterdam, The Netherlands. Medical writing support was provided by Venkateswarlu Bonala and Saimithra Thammara and design support by Sarma Vajhula, all of Novartis Healthcare Pvt. Ltd., Hyderabad, India. The final responsibility for the content lies with the authors.

Copyright © 2023 Novartis Pharma AG. All rights reserved.



Scan this QR code to download a copy of the poster

Visit the web at: <https://bit.ly/ectrims2023>.

Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors

Presenter email address: g.hengstman@upendo.nl